Join

Compare · ENLV vs LLY

ENLV vs LLY

Side-by-side comparison of Enlivex Ltd. (ENLV) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both ENLV and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • LLY is the larger of the two at $1.09T, about 10658.5x ENLV ($101.8M).
  • Over the past year, ENLV is down 68.7% and LLY is up 49.6% - LLY leads by 118.2 points.
  • Both names hit the wire about 8 times in the past 4 weeks.
  • LLY has more recent analyst coverage (25 ratings vs 0 for ENLV).
PerformanceENLV-68.67%LLY+49.58%
2025-07-15+0.00%2026-07-14
MetricENLVLLY
Company
Enlivex Ltd.
Eli Lilly and Company
Price
$6.11-9.62%
$1154.26-2.51%
Market cap
$101.8M
$1.09T
1M return
-40.79%
-0.54%
1Y return
-68.67%
+49.58%
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NYSE
IPO
2014
News (4w)
8
8
Recent ratings
0
25
ENLV

Enlivex Ltd.

Enlivex Therapeutics Ltd. operates as a clinical stage immunotherapy company. It is developing Allocetra, an off-the-shelf cell therapy designed to reprogram macrophages into homeostatic state. Resetting non-homeostatic macrophages into homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. Diseases, such as solid cancers, sepsis, COVID-19, and others reprogram macrophages out of homeostatic state. Its Allocetra has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents. The company has a research collaboration with Yale Cancer Center for the assessment of Allocetra to enhance the activity of checkpoint inhibitors in solid tumors. Enlivex Therapeutics Ltd. was incorporated in 2005 and is headquartered in Nes Ziona, Israel.

LLY

Eli Lilly and Company

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Latest ENLV

Latest LLY